Blue Diamond
| Address | 136, Changgyeonggung-ro, Jongno-gu, Seoul, Republic of Korea (03127) | ||
|---|---|---|---|
| Telephone | +82-2-740-4324 | Fax | +82-2-744-0682 |
| Website | https://pharm.boryung.co.kr/eng/index.do | jschoi1206@boryung.co.kr | |
Boryung Pharmaceutical strives to be a company which will continue to practice ‘contributing to the health of mankind’ by preparing for the future and taking on challenges with innovation. Through our best efforts, Boryung Pharmaceutical has been accomplishing our mission of ‘contributing to the health of mankind’ and ‘practicing interdependence based on humanism’ ever since we were founded in 1963. From the times when our people sweat and toiled in the economic fronts, we have made every effort to free everyone from the pains of disease through constant research and producing high-quality medicine, even making efforts to ensure accurate delivery. As a result, the people of Korea have come to love our products, products such as Gelfos M, Yonggaksan, and Gu-sim, and we are proud that we have become the company that is now so familiar to all. Now, our country’s economy is at a crossroads to join the ranks of developed countries. Social and cultural aspects of our country already show signs of being in the advanced country stage. A few representative reflection of being in the advanced stage are low birth rates and a large increase in diseases due to aging population. Thus, the people of Korea are more keen on enjoying healthy lives. To keep pace with these changes, Boryung Pharmaceutical plans to continue the focus on research and development of new drugs and employing advanced marketing techniques, thereby producing superior pharmaceutical products that increase the ‘quality of life’. In order to accomplish this, Boryung Pharmaceutical will pursue continuous and intense innovation. In 2017, we had proclaimed a new vision of ‘ Lifetime Care Company for better life quality by best clinical based science’, by this, we are implementing and planning specific plans for innovated products, ingenious reconstruction of process and manpower. Boryung Pharmaceutical is a company that prepares for the future by constantly facing challenges with innovation. With this in mind, we strive to realize our ultimate goal of ‘contributing to the health of mankind.’Therefore, we ask for your interests and supports. Thank you.
Onbevzi is a cancer medicine that is used to treat adults with the following cancers: - cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body; - breast cancer that has spread to other parts of the body; - a type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Onbevzi can be used in non-small cell lung cancer unless it originates in cells of a particular type (called squamous cells); - cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere; - cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment; - cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or spread to other parts of the body. Onbevzi is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work. Onbevzi is a ‘biosimilar medicine’. This means that Onbevzi is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Onbevzi is Avastin. Onbevzi contains the active substance bevacizumab.
Samfenet is a biosimilar of trastuzumab and received marketing approval based on the results of efficacy equivalence to trastuzumab. This study is a phase 2 study to investigate the efficacy of Samfenet in combination with cytotoxic agents in patients with HER2-positive solid tumors. samfenet is a cancer medicine that is used to treat adults with the following cancers: - early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable. It can also be used earlier in treatment, in combination with chemotherapy. For tumours that are locally advanced (including those that are inflammatory) or more than 2 cm wide, Ontruzant is used before surgery in combination with chemotherapy and then again after surgery on its own; - metastatic breast cancer (cancer that has spread to other parts of the body). It is used on its own in patients in whom previous treatments have failed. It is also used in combination with other cancer medicines: with paclitaxel or docetaxel, or with another class of medicines called aromatase inhibitors; metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or 5‑fluorouracil (other cancer medicines). The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, SAMFENET(Ontruzant) has been shown to have a comparable quality, safety and effectiveness to Herceptin. Therefore, the Agency’s view was that, as for Herceptin, the benefit outweighs the identified risk and SAMFENET(Ontruzant) should be given marketing authorisation.
Irinotecan, sold under the brand name CAMPTO(Camptosar) among others, is a medication used to treat colon cancer, and small cell lung cancer. For colon cancer it is used either alone or with fluorouracil. For small cell lung cancer it is used with cisplatin. It is given intravenously. Common side effects include diarrhea, vomiting, bone marrow suppression, hair loss, shortness of breath, and fever. Other severe side effects include blood clots, colon inflammation, and allergic reactions. Those with two copies of the UGT1A1*28 gene variant are at higher risk for side effects. Use during pregnancy can result in harm to the baby. Irinotecan is a topoisomerase inhibitor -- it blocks the topoisomerase 1 enzume, resulting in DNA damage and cell death. Irinotecan was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is made from the natural compound camptothecin which is found in the Chinese ornamental tree Camptotheca acuminata.
Oxaliplatin, sold under the brand name OXALITIN , is a cancer medication used to treat colorectal cancer Often it is used together with fluorouracil and folinic acid (leucovorin) in advanced cancer. It is given by injection into a vein. Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts. Other serious side effects include allergic reactions. Use in pregnancy is known to harm the baby. Oxaliplatin is in the platinum-based antineoplastic family of medications.It is believed to work by blocking the duplication of DNA.
Gemcitabine, with brand names including Gemzar, is a chemotherapy medication. It treats cancers including testicular cancer, breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. It is administered by intravenous infusion.It acts against neoplastic growth, and it inhibits the replication of Orthohepevirus A, the causative agent of Hepatitis E, through upregulation of interferon signaling. Common side effects include bone marrow suppression, liver and kidney problems, nausea, fever, rash, shortness of breath, mouth sores, diarrhea, neuropathy, and hair loss.Use during pregnancy will likely result in fetal harm. Gemcitabine is in the nucleoside analog family of medication.It works by blocking the creation of new DNA, which results in cell death. Gemcitabine was patented in 1983 and was approved for medical use in 1995.Generic versions were introduced in Europe in 2009 and in the US in 2010. It is on the WHO Model List of Essential Medicines.
Megestrol acetate (MGA), sold under the brand name Megace among others, is a progestin medication which is used mainly as an appetite stimulant to treat wasting syndromes such as cachexia It is also used to treat breast cancer and endometrial cancer, and has been used in birth control. MGA is generally formulated alone, although it has been combined with estrogens in birth control formulationsIt is usually taken by mouth. Side effects of MGA include increased appetite, weight gain, vaginal bleeding, nausea, edema, low sex hormone levels, sexual dysfunction, osteoporosis, cardiovascular complications, glucocorticoid effects, and others. MGA is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak partial androgenic activity, weak glucocorticoid activity, and no other important hormonal activity. Due to its progestogenic activity, MGA has antigonadotropic effects. The mechanism of action of the appetite stimulant effects of MGA is unknown. MGA was discovered in 1959 and was introduced for medical use, specifically in birth control pills, in 1963. It may be considered a "first-generation" progestin. The medication was withdrawn in some countries in 1970 due to concerns about mammary toxicity observed in dogs, but this turned out not to apply to humans.MGA was approved for the treatment of endometrial cancer in 1971 and wasting syndromes in 1993. It is marketed widely throughout the world.It is available as a generic medication.
Neulasta (pegfilgrastim) is a colony-stimulating factor, a man-made form of a protein that stimulates the growth of white blood cells, used to decrease the incidence of infection, by treating neutropenia, a lack of certain white blood cells caused by receiving cancer chemotherapy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy.
